PMGC Holdings Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
1.740
+0.060 (3.57%)
Jun 3, 2026, 10:51 AM EDT - Market open
PMGC Holdings Revenue
PMGC Holdings had revenue of $681.99K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $1.27M. In the year 2025, PMGC Holdings had annual revenue of $590.08K.
Revenue (ttm)
$1.27M
Revenue Growth
n/a
P/S Ratio
6.00
Revenue / Employee
$37,414
Employees
34
Market Cap
7.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 590.08K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 766.28K | 765.45K | 92,557.44% |
| Dec 31, 2021 | 827.00 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionELAB News
- 2 days ago - PMGC to buy 76% interest in precision machining, contract manufacturing company - TheFly
- 2 days ago - PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets - GlobeNewsWire
- 16 days ago - GB Capital Ltd. Co-Advises on the Acquisition of A&B Aerospace Inc. - GlobeNewsWire
- 19 days ago - PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q1 2026 Results and Files Form 10-Q; Total Assets Reach Over $26.0 Million, Up 102% from Year-End 2025 and 193% Year-over-Year - GlobeNewsWire
- 21 days ago - PMGC acquires A&B Aerospace, terms undisclosed - TheFly
- 21 days ago - PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc. - GlobeNewsWire
- 5 weeks ago - UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders - GlobeNewsWire
- 5 weeks ago - NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans - GlobeNewsWire